168 related articles for article (PubMed ID: 34130863)
1. High-risk Surgically Resected Renal Cell Carcinoma: Is There a Role for Adjuvant VEGF-TKI Inhibitors?
Fallara G; Bandini M; Larcher A; Pederzoli F; Karakiewicz P; Tian Z; Briganti A; Necchi A; Salonia A; Bertini R; Montorsi F; Bex A; Capitanio U
Curr Probl Cancer; 2021 Dec; 45(6):100759. PubMed ID: 34130863
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis.
Laukhtina E; Quhal F; Mori K; Sari Motlagh R; Pradere B; Schuettfort VM; Mostafaei H; Katayama S; Grossmann NС; Rajwa P; Resch I; Enikeev D; Karakiewicz PI; Shariat SF; Schmidinger M
Urol Oncol; 2021 Nov; 39(11):764-773. PubMed ID: 34400065
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.
Sun M; Marconi L; Eisen T; Escudier B; Giles RH; Haas NB; Harshman LC; Quinn DI; Larkin J; Pal SK; Powles T; Ryan CW; Sternberg CN; Uzzo R; Choueiri TK; Bex A
Eur Urol; 2018 Nov; 74(5):611-620. PubMed ID: 29784193
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy.
Laukhtina E; Quhal F; Mori K; Sari Motlagh R; Rajwa P; Yanagisawa T; Mostafaei H; König F; Aydh A; Pradere B; Enikeev D; Karakiewicz PI; Schmidinger M; Shariat SF
Eur Urol Oncol; 2022 Feb; 5(1):120-124. PubMed ID: 34992006
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
Motzer RJ; Ravaud A; Patard JJ; Pandha HS; George DJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Casey M; Serfass L; Pantuck AJ; Staehler M
Eur Urol; 2018 Jan; 73(1):62-68. PubMed ID: 28967554
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant Tyrosine Kinase Inhibitors in Treatment of Renal Cell Carcinoma: A Meta-Analysis of Available Clinical Trials.
Massari F; Di Nunno V; Mollica V; Graham J; Gatto L; Heng D
Clin Genitourin Cancer; 2019 Apr; 17(2):e339-e344. PubMed ID: 30704796
[TBL] [Abstract][Full Text] [Related]
7. Association between age and sex and mortality after adjuvant therapy for renal cancer.
Mamtani R; Wang XV; Gyawali B; DiPaola RS; Epperson CN; Haas NB; Dutcher JP
Cancer; 2019 May; 125(10):1637-1644. PubMed ID: 30620389
[TBL] [Abstract][Full Text] [Related]
8. Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials.
Karakiewicz PI; Zaffuto E; Kapoor A; Basappa NS; Bjarnason GA; Blais N; Breau RH; Canil C; Drachenberg D; Hotte SJ; Jeldres C; Jewett MAS; Kassouf W; Kollmannsberger C; Lavallée LT; Maloni R; Patenaude F; Pouliot F; Reaume MN; Sabbagh R; Shayegan B; So A; Soulières D; Tanguay S; Wood L; Bandini M
Can Urol Assoc J; 2018 Jun; 12(6):173-180. PubMed ID: 29877179
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.
Chamie K; Donin NM; Klöpfer P; Bevan P; Fall B; Wilhelm O; Störkel S; Said J; Gambla M; Hawkins RE; Jankilevich G; Kapoor A; Kopyltsov E; Staehler M; Taari K; Wainstein AJA; Pantuck AJ; Belldegrun AS
JAMA Oncol; 2017 Jul; 3(7):913-920. PubMed ID: 27787547
[TBL] [Abstract][Full Text] [Related]
10. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.
Motzer RJ; Haas NB; Donskov F; Gross-Goupil M; Varlamov S; Kopyltsov E; Lee JL; Melichar B; Rini BI; Choueiri TK; Zemanova M; Wood LA; Reaume MN; Stenzl A; Chowdhury S; Lim HY; McDermott R; Michael A; Bao W; Carrasco-Alfonso MJ; Aimone P; Voi M; Doehn C; Russo P; Sternberg CN;
J Clin Oncol; 2017 Dec; 35(35):3916-3923. PubMed ID: 28902533
[TBL] [Abstract][Full Text] [Related]
11. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-analysis.
Raphael J; Vincent M; Boldt G; Shah PS; Rodrigues G; Blanchette P
Am J Clin Oncol; 2019 May; 42(5):440-445. PubMed ID: 30913091
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant Therapy in High-Risk Renal Cell Cancer: A Systematic Review and Meta-analysis.
Riaz IB; Faridi W; Husnain M; Malik SU; Sipra QUAR; Gondal FR; Xie H; Yadav S; Kohli M
Mayo Clin Proc; 2019 Aug; 94(8):1524-1534. PubMed ID: 31303430
[TBL] [Abstract][Full Text] [Related]
14. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
[TBL] [Abstract][Full Text] [Related]
15. Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies.
Ciccarese C; Iacovelli R; Brunelli M; Massari F; Bimbatti D; Fantinel E; De Marco V; Porcaro AB; Martignoni G; Artibani W; Tortora G
Eur J Cancer; 2017 Sep; 83():237-246. PubMed ID: 28756136
[TBL] [Abstract][Full Text] [Related]
16. Molecular Subtypes and Gene Expression Signatures as Prognostic Features in Fully Resected Clear Cell Renal Cell Carcinoma: A Tailored Approach to Adjuvant Trials.
Roussel E; Verbiest A; Kinget L; Boeckx B; Zucman-Rossi J; Couchy G; Caruso S; Job S; de Reyniès A; De Wever L; Baldewijns M; Van Poppel H; Joniau S; Lambrechts D; Albersen M; Beuselinck B
Clin Genitourin Cancer; 2021 Dec; 19(6):e382-e394. PubMed ID: 34362692
[TBL] [Abstract][Full Text] [Related]
17. Sarcomatoid features, necrosis, and grade are prognostic factors in metastatic clear cell renal cell carcinoma with vascular endothelial growth factor-targeted therapy.
Park JY; Lee JL; Baek S; Eo SH; Go H; Ro JY; Cho YM
Hum Pathol; 2014 Jul; 45(7):1437-44. PubMed ID: 24784922
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: A Concluded Living Systematic Review and Meta-Analysis.
Riaz IB; Siddiqi R; Islam M; He H; Riaz A; Asghar N; Naqvi SAA; Warner JL; Murad MH; Kohli M
JCO Clin Cancer Inform; 2021 May; 5():588-599. PubMed ID: 34043431
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the pathologic inclusion criteria from contemporary adjuvant clinical trials for predicting disease progression after nephrectomy for renal cell carcinoma.
Kim SP; Crispen PL; Thompson RH; Weight CJ; Boorjian SA; Costello BA; Lohse CM; Leibovich BC
Cancer; 2012 Sep; 118(18):4412-20. PubMed ID: 22952032
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF?
Mollica V; Rizzo A; Di Nunno V; Santoni M; Cheng L; Lopez-Beltran A; Scarpelli M; Cimadamore A; Montironi R; Massari F
Transl Androl Urol; 2021 Mar; 10(3):1581-1587. PubMed ID: 33850792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
